U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07024147) titled 'JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma' on May 27.
Brief Summary: JWCAR239 is a CD19/CD20 CAR-T product. This trial is intended to evaluate the safety, PK/PD and efficacy of JWCAR239 in patients with B Cell Non-Hodgkin Lymphoma (B-NHL)
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
B-Cell Non-Hodgkin Lymphoma
Large B Cell Diffuse Lymphoma
Follicular Lymphoma
Marginal Zone B Cell Lymphoma
Mantle Cell Lymphoma (MCL)
Intervention:
BIOLOGICAL: JWCAR239
A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells targeting CD19/CD20
DRUG: Fludarabine
Administered according to...